Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Keymed Biosciences Co. Ltd. maintains 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units, reflecting a diverse range of subject matter within the pharmaceutical sector. The lack of overlap between examiners and art units suggests that each pending application is being treated as a separate technological track, requiring individual attention to the specific requirements of the 3 distinct art units.
PETRASH, HILARY ANN is the busiest examiner for this portfolio, currently overseeing 1 pending office action. Since there are 3 distinct examiners for the 3 pending office actions, the workload is spread across multiple individuals. This distribution across 3 distinct art units means that the prosecution strategy must account for the specific nuances of the different specialized groups within the biotechnology field. Managing this portfolio involves navigating the distinct procedural expectations of 3 distinct examiners, as no centralization exists in the current pending workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PETRASH, HILARY ANN | 1 | 64.5% | +51.7% |
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18910550 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | PETRASH, HILARY ANN | — |
| 18038159 | BISPECIFIC ANTIBODY AND USE THEREOF | GODDARD, LAURA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031731 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | HADDAD, MAHER M | 104d overdue |
| 18910550 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | PETRASH, HILARY ANN | — |
| 18038159 | BISPECIFIC ANTIBODY AND USE THEREOF | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1642 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18910550 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | PETRASH, HILARY ANN | 1644 | §101§112DP | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18038159 | BISPECIFIC ANTIBODY AND USE THEREOF | GODDARD, LAURA B | 1642 | §103§112 | Final Rejection | — | Pending | May 22, 2023 |
| 18031731 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | HADDAD, MAHER M | 1641 | DP | Final Rejection | 104d overdue | Pending | Apr 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial